Biopharmaceutical company Ascendis Pharma A/S (ASND) is on the brink of a pivotal moment with its flagship candidate, TransCon CNP, as it undergoes priority review by the U.S. FDA for the treatment of achondroplasia in children. Mark your calendars for November 30, 2025, when the PDUFA decision is expected. This could meaningfully impact the company's valuation and strategic future.
Meanwhile, the significance continues across the Atlantic, as a parallel marketing application has been filed in Europe. The journey ahead for this groundbreaking program is shaping up to be both critical and promising!
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com